Florian Baudin1, Eric Benzenine2, Anne-Sophie Mariet2,3,4,5, Alain M Bron1,6, Vincent Daien7,8, Jean François Korobelnik9,10, Catherine Quantin2,3,4,5, Catherine Creuzot-Garcher1,6. 1. Department of Ophthalmology, Dijon University Hospital, Dijon, France. 2. Department of Biostatistics and Bioinformatics, Dijon University Hospital, Franche-Comté University, Dijon, France. 3. Institut National de la Santé et de la Recherche Medicale (INSERM), Centre d'Investigation Clinique 1432, Dijon, France. 4. Clinical Investigation Center, Clinical Epidemiology/Clinical Trials Unit, Dijon University Hospital, Dijon, France. 5. Department of Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases, INSERM, Université de Versailles Saint-Quentin-en-Yvelines, Institut Pasteur, Université Paris-Saclay, Paris, France. 6. Eye and Nutrition Research Group, Bourgogne Franche-Comté University, Dijon, France. 7. Department of Ophthalmology, University Hospital of Montpellier, Montpellier, France. 8. INSERM U1061, University of Montpellier, Montpellier, France. 9. Department of Ophthalmology, University Hospital of Bordeaux, Bordeaux, France. 10. INSERM U1219, Population Health Research Center, Bordeaux, France.
Abstract
Importance: The number of patients affected by retinal diseases treated with intravitreal injections (IVTs) has resulted in a rapidly growing number of procedures. One of the worst complications after these injections is endophthalmitis. Objective: To evaluate the incidence of acute endophthalmitis after IVTs of corticosteroids or anti-vascular endothelial growth factor (anti-VEGF) agents. Design, Setting, and Participants: This population-based cohort study included patients undergoing IVTs from January 1, 2012, through December 31, 2015, in France. Data were acquired from the French medical-administrative database (Système National d'Information Inter-Régime de l'Assurance Maladie), which collects hospitalization discharge abstracts and out-of-hospital care information for the whole country. Data were analyzed from March through July 2017. Exposures: Intravitreal injections of corticosteroid or anti-VEGF agents. Main Outcomes and Measures: Incidence of acute endophthalmitis within 6 weeks after IVT by means of billing codes from a national database. Results: During the study period, 1 811 977 IVTs of corticosteroids or anti-VEGF agents performed on 254 927 patients (60.4% female; median age, 79 years [interquartile range, 70-85 years]) were analyzed. A total of 444 acute endophthalmitis cases (crude incidence, 0.0245%) were recorded. In multivariable analysis, which did not include adjustment for when the endophthalmitis occurred during the study period, the risk of endophthalmitis was lower in male patients (incidence rate ratio [IRR], 0.78; 95% CI, 0.63-0.96; P = .02), higher for corticosteroids than for anti-VEGF agents (IRR, 3.21; 95% CI, 2.33-4.44; P < .001), and higher for nonprefilled syringes of anti-VEGF medications than prefilled syringes for ranibizumab (IRR, 1.63; 95% CI, 1.15-2.30) and aflibercept (IRR, 1.82; 95% CI, 1.25-2.66; P < .001). Conclusions and Relevance: The findings from this study of a nationwide database appear to have confirmed the low incidence rate of acute endophthalmitis after IVTs of corticosteroids or anti-VEGF agents. Although an association may not necessarily indicate a cause and effect, the risk for acute endophthalmitis after IVTs appeared to be higher for corticosteroids compared with anti-VEGF agents, while a lower risk of endophthalmitis appeared to be found with prefilled syringes of anti-VEGF medications.
Importance: The number of patients affected by retinal diseases treated with intravitreal injections (IVTs) has resulted in a rapidly growing number of procedures. One of the worst complications after these injections is endophthalmitis. Objective: To evaluate the incidence of acute endophthalmitis after IVTs of corticosteroids or anti-vascular endothelial growth factor (anti-VEGF) agents. Design, Setting, and Participants: This population-based cohort study included patients undergoing IVTs from January 1, 2012, through December 31, 2015, in France. Data were acquired from the French medical-administrative database (Système National d'Information Inter-Régime de l'Assurance Maladie), which collects hospitalization discharge abstracts and out-of-hospital care information for the whole country. Data were analyzed from March through July 2017. Exposures: Intravitreal injections of corticosteroid or anti-VEGF agents. Main Outcomes and Measures: Incidence of acute endophthalmitis within 6 weeks after IVT by means of billing codes from a national database. Results: During the study period, 1 811 977 IVTs of corticosteroids or anti-VEGF agents performed on 254 927 patients (60.4% female; median age, 79 years [interquartile range, 70-85 years]) were analyzed. A total of 444 acute endophthalmitis cases (crude incidence, 0.0245%) were recorded. In multivariable analysis, which did not include adjustment for when the endophthalmitis occurred during the study period, the risk of endophthalmitis was lower in male patients (incidence rate ratio [IRR], 0.78; 95% CI, 0.63-0.96; P = .02), higher for corticosteroids than for anti-VEGF agents (IRR, 3.21; 95% CI, 2.33-4.44; P < .001), and higher for nonprefilled syringes of anti-VEGF medications than prefilled syringes for ranibizumab (IRR, 1.63; 95% CI, 1.15-2.30) and aflibercept (IRR, 1.82; 95% CI, 1.25-2.66; P < .001). Conclusions and Relevance: The findings from this study of a nationwide database appear to have confirmed the low incidence rate of acute endophthalmitis after IVTs of corticosteroids or anti-VEGF agents. Although an association may not necessarily indicate a cause and effect, the risk for acute endophthalmitis after IVTs appeared to be higher for corticosteroids compared with anti-VEGF agents, while a lower risk of endophthalmitis appeared to be found with prefilled syringes of anti-VEGF medications.
Authors: Chirag P Shah; Sunir J Garg; James F Vander; Gary C Brown; Richard S Kaiser; Julia A Haller Journal: Ophthalmology Date: 2011-06-25 Impact factor: 12.079
Authors: Denis Dossarps; Alain M Bron; Philippe Koehrer; Ludwig S Aho-Glélé; Catherine Creuzot-Garcher Journal: Am J Ophthalmol Date: 2015-04-16 Impact factor: 5.258
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Nadim Rayess; Ehsan Rahimy; Chirag P Shah; Jeremy D Wolfe; Eric Chen; Francis C DeCroos; Philip Storey; Sunir J Garg; Jason Hsu Journal: Br J Ophthalmol Date: 2015-11-19 Impact factor: 4.638
Authors: Laura S Edison; Hope O Dishman; Melissa J Tobin-D'Angelo; C Richard Allen; Alice Y Guh; Cherie L Drenzek Journal: Emerg Infect Dis Date: 2015-01 Impact factor: 6.883
Authors: Rebecca E H Whiting; Grace Robinson Kick; Juri Ota-Kuroki; Stefanie Lim; Leilani J Castaner; Cheryl A Jensen; Joseph Kowal; Annalisa Nguyen; Carley Corado; Charles A O'Neill; Martin L Katz Journal: Exp Eye Res Date: 2020-07-04 Impact factor: 3.770
Authors: Samir N Patel; Jason Hsu; Meera D Sivalingam; Allen Chiang; Richard S Kaiser; Sonia Mehta; Carl H Park; Carl D Regillo; Arunan Sivalingam; James F Vander; Allen C Ho; Sunir J Garg Journal: Am J Ophthalmol Date: 2020-09-02 Impact factor: 5.258
Authors: Yongseok Mun; Seng Chan You; Da Yun Lee; Seok Kim; Yoo-Ri Chung; Kihwang Lee; Ji Hun Song; Young Gun Park; Young Hoon Park; Young-Jung Roh; Se Joon Woo; Kyu Hyung Park; Rae Woong Park; Sooyoung Yoo; Dong-Jin Chang; Sang Jun Park Journal: Epidemiol Health Date: 2021-11-09